ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sandoz says it will invest $50 million to expand production capacity for finished-dosage penicillin at its plant in Kundl, Austria. The company, a leading supplier of generic and biosimilar medicines, last year announced a $100 million investment in the site to manufacture the active pharmaceutical ingredient (API) in oral amoxicillin. The investments are part of Sandoz’s $250 million expansion in antibiotics manufacturing at its European sites, including a $50 million project unveiled in 2021 to bolster sterile API production in Palafolls, Spain.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter